Brief: Immunovia Says CMS Sets Prelim Price Of $897 For Pancreasure Test
Sept 11 (Reuters) - Immunovia AB (publ) IMMNOV.ST: CMS SETS PRELIMINARY PRICE OF $897 FOR PANCREASURE TEST CMS FINAL PAYMENT DECISION EXPECTED NOVEMBER, EFFECTIVE JAN 2026 Source text: ID:nMFN2TJzMG Further company coverage: IMMNOV.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Immunovia AB (publ)
See all newsBrief: Immunovia Publishes Data On Pancreasure In Hereditary, Familial High-Risk Individuals
Brief: Immunovia To Carry Out Rights Issue Of About SEK 63 Million
Sweden's Immunovia Q2 sales rise on PancreaSure test uptake
Brief: Immunovia Reports Q2 Operating Loss Of SEK 22.8 Million
Brief: PancreaSure Achieves 88% Sensitivity In Immunovia Study